다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) 뉴스

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ALTH

<< 이전 16 17 18 19 20 21 22 23 24 25 26 27 28 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2006/06/05	22:00	PR Newswire (US)	Allos Therapeutics' EFAPROXYN(TM) Found to Reduce Tumor Hypoxia and HIF-1-alpha Expression in Human Breast Cancer Xenografts	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/05/26	05:33	PR Newswire (US)	Allos Therapeutics Reports Restricted Stock Grant Under Nasdaq Marketplace Rule 4350	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/05/09	21:00	PR Newswire (US)	Allos Therapeutics Reports First Quarter 2006 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/04/04	21:00	PR Newswire (US)	Interim Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 3 Trial	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/03/10	22:00	PR Newswire (US)	Allos Therapeutics Appoints Paul L. Berns as President and CEO	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/03/06	22:00	PR Newswire (US)	Allos Therapeutics Reports 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/03/01	22:00	PR Newswire (US)	Allos Therapeutics to Present at the 2006 Cowen Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/02/14	22:00	PR Newswire (US)	Scheduled Combination of Allos Therapeutics' Pralatrexate Plus Gemcitabine Proves Superior to Methotrexate Plus Cytarabine in Mo	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/02/01	22:00	PR Newswire (US)	Allos Therapeutics to Present at the 2006 BIO CEO & Investor Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/01/17	09:22	PR Newswire (US)	Allos Therapeutics Announces CEO Succession Plans	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/01/03	22:00	PR Newswire (US)	Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases Ori	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/12/12	22:02	PR Newswire (US)	Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality of Life in Patients With Brain Metastases Originating F	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/12/12	22:00	PR Newswire (US)	PDX Shows Promising Activity in Patients With Resistant T-Cell Lymphomas	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/11/17	22:02	PR Newswire (US)	Allos Therapeutics Appoints Timothy P. Lynch to Board of Directors	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/11/17	22:01	PR Newswire (US)	Interim Phase 1 Data on RH1 Presented at AACR-NCI-EORTC Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/11/16	22:00	PR Newswire (US)	Data From Phase 1 Clinical Trial of PDX (Pralatrexate) to be Presented at American Society of Hematology Annual Meeting	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/11/09	22:02	PR Newswire (US)	Allos Therapeutics Reports Third Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/11/08	22:02	PR Newswire (US)	Data on EFAPROXYN(TM) and RH1 to be Presented at Upcoming Scientific Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/10/22	01:02	PR Newswire (US)	Allos Therapeutics Announces Dismissal of Securities Class Action Lawsuit	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/10/13	22:01	PR Newswire (US)	Allos Therapeutics to Present at the 2005 BIO Investor Forum	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/10/12	07:06	PR Newswire (US)	Allos Therapeutics Announces Withdrawal of European Marketing Authorization Application for REVAPROXYN(TM)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/09/22	22:00	PR Newswire (US)	Allos Therapeutics to Present at the UBS Global Life Sciences Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/09/07	22:02	PR Newswire (US)	Allos Therapeutics to Present at the Bear Stearns Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/09/01	22:00	PR Newswire (US)	Results Published in Journal of Clinical Oncology Demonstrate Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Recei	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/08/08	22:01	PR Newswire (US)	Allos Therapeutics Reports Second Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/06/17	04:28	PR Newswire (US)	Allos Therapeutics and Hovione Enter Into Manufacturing Agreement for EFAPROXYN(TM) Bulk Drug Substance	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/05/20	07:46	PR Newswire (US)	Allos Therapeutics Announces Stockholder Approval of Share Exchange	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/05/19	22:00	PR Newswire (US)	Allos Therapeutics to Present at the Needham & Company Biotechnology Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/05/05	22:01	PR Newswire (US)	Allos Therapeutics Reports First Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2005/03/11	20:00	PR Newswire (US)	Allos Therapeutics to Present at SG Cowen's Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)

검색 관련기사 보기:NASDAQ:ALTH

<< 이전 16 17 18 19 20 21 22 23 24 25 26 27 28 다음 >>

JP Morgan Chase

Health Care Select Sector

Energy Select Sector SPDR

American Express

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관